Systemic tocopherols and F2-isoprostanes and the risk of Alzheimer's disease and dementia: a prospective population-based study
2009 (English)In: Journal of Alzheimer's Disease, ISSN 1387-2877, Vol. 18, no 1, 71-78 p.Article in journal (Refereed) Published
Oxidative stress in the brain is suggested to be involved in the pathophysiology of Alzheimer's disease (AD). In this study, serum alpha- and gamma-tocopherol, the two major systemic antioxidants, were analyzed at two examinations of the ULSAM-study, a longitudinal, community-based study of elderly men (age 70, n = 616 and age 77, n = 761). In addition, urinary F2-isoprostane levels, as markers of systemic oxidative stress, were analyzed at the age of 77 in this cohort (n = 679). Cox regression analyses were used to examine associations between serum alpha-, gamma-tocopherol and urinary F2-isoprostane levels and AD, any type of dementia (all-cause dementia) and non-AD dementia. On follow-up (median, 12.3 years), 40 subjects developed AD and 86 subjects developed all-cause dementia. Serum alpha- and gamma-tocopherol or urinary F2-isoprostane levels were not associated with the future risk of AD or dementia. In conclusion, systemic serum alpha- and gamma-tocopherol and urinary F2-isoprostane levels are not associated with the future risk of AD or dementia and do not seem to be useful predictors of clinical AD or dementia.
Place, publisher, year, edition, pages
2009. Vol. 18, no 1, 71-78 p.
Alzheimer's disease, dementia, isoprostanes, oxidative stress, vitamins
Medical and Health Sciences
IdentifiersURN: urn:nbn:se:uu:diva-120823DOI: 10.3233/JAD-2009-1125ISI: 000269629500007PubMedID: 19542632OAI: oai:DiVA.org:uu-120823DiVA: diva2:304001